Hematology/Oncology

Top Story

Toxicity rates high after cetuximab therapy for anal carcinoma

Toxicity rates high after cetuximab therapy for anal carcinoma
February 26, 2017

The addition of cetuximab to chemoradiotherapy was associated with a lower incidence of locoregional failure in patients with squamous cell carcinoma of the anal canal, according to results from the phase 2 Eastern Cooperative Oncology Group—American College of Radiology Imaging Network Cancer Research Group Trial.

However, locoregional failure still occurred in some patients, and toxicity rates were high.

In the Journals Plus

Early palliative care may improve quality of life in patients with lung, gastrointestinal cancers

February 25, 2017
Early integration of palliative care for patients with newly diagnosed incurable gastrointestinal and lung cancers improved quality of life, reduced depression symptoms…
In the Journals Plus

Ruxolitinib controls disease-related symptoms in CLL

February 24, 2017
Ruxolitinib led to symptom improvement, including a reduction in fatigue, among patients with chronic lymphocytic leukemia who did not require systemic therapy…
In the Journals

Immediate postmastectomy breast reconstruction may be a safe, effective option

February 24, 2017
In the postmastectomy radiation setting, immediate autologous breast reconstruction yielded similar complication and satisfaction rates as delayed reconstruction. The…
Meeting News

Researchers identify factors associated with survival in patients with blast phase CML

February 24, 2017
“Previously unknown” prognostic factors – including older age at diagnosis, high bone marrow blast percentage, higher LDH levels and previous tyrosine…
More News Headlines »
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video
Meeting News Coverage

VIDEO: Immunotherapy holds potential to eliminate dormant, lethal cancer cells

January 11, 2017
More »
Featured
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement